Trials / Completed
CompletedNCT00468182
Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (actual)
- Sponsor
- Rutgers, The State University of New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether interferon-beta impairs the ability of plasmacytoid dendritic cells to promote pathogenic immune responses in patients with multiple sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon-beta 1b (Betaseron) | Treatment of patients with FDA-approved Rx |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2007-05-02
- Last updated
- 2015-05-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00468182. Inclusion in this directory is not an endorsement.